Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors

TAIPEI and SAN DIEGO , Dec. 10, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company developing first-in-class therapies for difficult-to-treat cancers, today announced a clinical supply agreement with BeOne Medicines, a global oncology company. This agreement will supply a global, multi-center Phase 1b/2a clinical trial to evaluate Senhwa's lead compound Pidnarulex (CX-5461) in combination with BeOne's tislelizumab, a PD-1 inhibitor, in patients with advanced solid tumors, including pancreatic ductal adenocarcinoma (PDAC) and immune checkpoint inhibitor (ICI)-refractory melanoma.

PRNewsWire • Dec 10, 2025

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne's ASH data reinforce BRUKINSA® (zanubrutinib) as the foundational Bruton's tyrosine kinase inhibitor (BTKi) of choice. “At.

Business Wire • Dec 8, 2025

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses.

Business Wire • Dec 7, 2025

BeOne Medicines Continues To Execute In Q3

BeOne Medicines maintains Strong Buy as Brukinsa and Tevimbra drive robust growth and pipeline catalysts approach. Q3 2025 marked a pivotal inflection point with 41% YoY sales growth and positive earnings; Brukinsa sales topped $1B, up 51% YoY. Sonrotoclax, a BCL2 inhibitor, received FDA Priority Review, positioning ONC for a major 2026 pipeline catalyst.

Seeking Alpha • Dec 4, 2025

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton's tyrosine kinase (BTK) inhibitor. “Sonrotoclax is a.

Business Wire • Nov 26, 2025

Artisan International Small-Mid Fund Q3 2025 Performance Review

Security selection in industrials and a notable overweight to the software industry within information technology were the key detractors from relative returns. Health care is among the three weakest performing sectors and is the portfolio's biggest relative detractor in relative returns YTD. Geographically, international markets have led domestic markets notably YTD, largely reflecting depressed valuations after a multiyear lag.

Seeking Alpha • Nov 26, 2025

This Pharma Stock Owned By Top Fund Flirts With Entry As Earnings Surge 452%

Pharma stocks can be the most rewarding of all equities. BeOne Medicines is offering a chance to climb on board amid a powerful rally.

Investors Business Daily • Nov 21, 2025

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, advances its vision to become the world's leading oncology company with extensive new data from its differentiated hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, December 6-9. Nearly 50 abstracts have been accepted, including six oral presentations, featuring the company's three transformative appr.

Business Wire • Nov 20, 2025

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including.

Business Wire • Nov 17, 2025

BeOne Medicines AG (ONC) Presents at Jefferies London Healthcare Conference 2025 Transcript

BeOne Medicines AG ( ONC ) Jefferies London Healthcare Conference 2025 November 17, 2025 11:00 AM EST Company Participants John Oyler - Co-Founder, Executive Chairman & CEO Aaron Rosenberg - Chief Financial Officer Mark Lanasa - Senior VP & Chief Medical Officer for Solid Tumors Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division All right. Good afternoon, everyone.

Seeking Alpha • Nov 17, 2025